Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts
Zhouling Xie, Shuzeng Hou, Xiaoxiao Yang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 9, pp. 6356-6389
Closed Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy
Zhifeng Zou, Lei Yang, Hui-Jun Nie, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 8, pp. 1740-1751
Closed Access | Times Cited: 10
Interactions between lncRNAs and cyclins/CDKs complexes; key players in determining cancer cell response to CDKs inhibitors
B Saeed, Abhinav Kumar, Enwa Felix Oghenemaro, et al.
Experimental Cell Research (2025) Vol. 445, Iss. 2, pp. 114406-114406
Closed Access
Structure-Guided Discovery of Novel N4-(Substituted Thiazol-2-yl)-N2-(4-Substituted phenyl)pyrimidine-2,4-Diamines as Potent CDK2 and CDK9 Dual Inhibitors with High Oral Bioavailability
Bei Zhang, Yan-Hong Li, Yukang Lin, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Screening through Lead Optimization of High Affinity, Allosteric Cyclin-Dependent Kinase 2 (CDK2) Inhibitors as Male Contraceptives That Reduce Sperm Counts in Mice
Erik B. Faber, Nan Wang, Kristen John, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 3, pp. 1928-1940
Closed Access | Times Cited: 16
Discovery of novel macrocyclic derivatives as potent and selective cyclin-dependent kinase 2 inhibitors
Pengpeng Niu, Yanxin Tao, Qingyuan Meng, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 104, pp. 117711-117711
Closed Access | Times Cited: 5
Accelerating PROTACs Discovery Through a Direct‐to‐Biology Platform Enabled by Modular Photoclick Chemistry
Ke‐Nian Yan, Yong‐Qiang Nie, Jiayu Wang, et al.
Advanced Science (2024) Vol. 11, Iss. 26
Open Access | Times Cited: 4
Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets
Shenglan Liu, Wei Dai, Bei Jin, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Discovery of novel and potent CDK8 inhibitors for the treatment of acute myeloid leukaemia
Zhuoying Chen, Quan Wang, Yao Yao Yan, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2024) Vol. 39, Iss. 1
Open Access | Times Cited: 3
Deriving general structure–activity/selectivity relationship patterns for different subfamilies of cyclin-dependent kinase inhibitors using machine learning methods
Sara Kaveh, Ahmad Mani‐Varnosfaderani, M. S. Neiband
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Ligand- and structure-based identification of novel CDK9 inhibitors for the potential treatment of leukemia
Huimin Zhang, Jindi Huang, Rui Chen, et al.
Bioorganic & Medicinal Chemistry (2022) Vol. 72, pp. 116994-116994
Closed Access | Times Cited: 16
Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors
Pengpeng Niu, Yanxin Tao, Guohao Lin, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6099-6118
Closed Access | Times Cited: 2
The Role of CDK20 Protein in Carcinogenesis
Sowmya Chivukula, Vasavi Malkhed
Current Drug Targets (2023) Vol. 24, Iss. 10, pp. 790-796
Closed Access | Times Cited: 6
Recent Advances in Synthetic Routes to Azacycles
Thu Anh Nguyen, Hee‐Kwon Kim
Molecules (2023) Vol. 28, Iss. 6, pp. 2737-2737
Open Access | Times Cited: 5
Design, synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel potent CDK7 inhibitors
Hongjin Zhang, Guohao Lin, Suyun Jia, et al.
Bioorganic Chemistry (2024) Vol. 148, pp. 107456-107456
Closed Access | Times Cited: 1
Design and synthesis of 7-azaindole derivatives as potent CDK8 inhibitors for the treatment of acute myeloid leukemia
Yumeng Wang, Cencen Lei, Quan Wang, et al.
RSC Medicinal Chemistry (2024) Vol. 15, Iss. 9, pp. 3180-3195
Open Access | Times Cited: 1
The Role of CDK Pathway Dysregulation and Its Therapeutic Potential in Soft Tissue Sarcoma
Johannes Tobias Thiel, Adrien Daigeler, Jonas Kolbenschlag, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3380-3380
Open Access | Times Cited: 10
Targeting Cyclin-Dependent Kinases: From Pocket Specificity to Drug Selectivity
Yaoguang Huang, Wenwu Liu, Changhao Zhao, et al.
European Journal of Medicinal Chemistry (2024) Vol. 275, pp. 116547-116547
Closed Access | Times Cited: 1
Protein engineering enables a soakable crystal form of human CDK7 primed for high-throughput crystallography and structure-based drug design
Manjeet Mukherjee, Philip J. Day, Duncan Laverty, et al.
Structure (2024) Vol. 32, Iss. 8, pp. 1040-1048.e3
Closed Access | Times Cited: 1
Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies
Abdusaid Saidahmatov, Jianan Li, Shihao Xu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 17, pp. 15220-15245
Closed Access | Times Cited: 1
In silico identification of novel CDK4 inhibitors for retinoblastoma.
Mukesh Kumar, V. C. Srivastava, Uma Devi, et al.
Chemical Physics Impact (2024), pp. 100743-100743
Open Access | Times Cited: 1
Discovery of a novel oral type Ⅰ CDK8 inhibitor against acute myeloid leukemia
Xing Xing Zhang, Yao Yao Yan, Xiao Ma, et al.
European Journal of Medicinal Chemistry (2023) Vol. 251, pp. 115214-115214
Closed Access | Times Cited: 4
Discovery and optimization of thieno[3,2-d]pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7
Hongjin Zhang, Guohao Lin, Suyun Jia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 263, pp. 115955-115955
Closed Access | Times Cited: 4
Cyclin-Dependent Kinases As Potential Targets for Colorectal Cancer: Past, Present and Future
Sonal M. Manohar
Future Medicinal Chemistry (2022) Vol. 14, Iss. 14, pp. 1087-1105
Closed Access | Times Cited: 7
A novel CDK8 inhibitor with poly-substituted pyridine core: Discovery and anti-inflammatory activity evaluation in vivo
Xing Chen, Yaoyao Yan, Cheng Xiu, et al.
Bioorganic Chemistry (2023) Vol. 133, pp. 106402-106402
Closed Access | Times Cited: 3
Identification of abemaciclib derivatives targeting cyclin-dependent kinase 4 and 6 using molecular dynamics, binding free energy calculation, synthesis, and pharmacological evaluation
Yanting Zhou, Xiandeng Li, Peifang Luo, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top